CardioVascular Dynamics announces patent approval for stent technology.IRVINE, Calif.--(BW HealthWire)--Feb. 4, 1997--CardioVascular Dynamics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CCVD CCVD Communauté de Communes du Val de Drôme CCVD Combustion Chemical Vapor Deposition ) Tuesday announced that it has been notified by the U.S. Patent Office that its patent application entitled "Two-Piece Bifurcated bi·fur·cate v. bi·fur·cat·ed, bi·fur·cat·ing, bi·fur·cates v.tr. To divide into two parts or branches. v.intr. To separate into two parts or branches; fork. adj. Intraluminal Graft for Repair of an Aneurysm aneurysm (ăn`y  rĭzəm), localized dilatation of a blood vessel, particularly an artery, or the heart. " has been approved and will be issued by the patent office. This patent is based on CVD's Self-Expanding Microporous Stent (SEMS SEMS Standardized Emergency Management System SEMS Screw and Washer Assemblies SEMS Student Emergency Medical Services (various universities) SEMS Support Enforcement Management System ) technology acquired during 1996. CVD CVD Cardiovascular disease, see there is currently developing this patented technology for a number of clinical applications, including peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. , treatment of aortic aneurysms, and coronary applications. CVD now has six issued U.S. patents protecting this technology. A number of U.S. and foreign patent applications are pending. Commenting on this new patent, CVD Chairman Michael Henson said, "Since acquiring this technology, we have filed two new patent applications, had one new patent issue and have completed the initial animal trials required to show the potential clinical value of selected product designs. We expect to continue to broaden our proprietary position with this technology and focus on initiating human clinical trials as quickly as possible." CVD develops and markets site-specific drug delivery catheters, combined angioplasty-drug delivery catheters, stent delivery catheters and vascular access products. -0- NOTE: Except for the historical information contained herein, the matters discussed in this news release may be forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals and clinical efficacy of, manufacturability of and market demand for products, among other matters discussed in this release, may cause actual results to differ significantly from the discussion of such matters in the forward-looking statements. Actual results may be affected by, among other things, risk and uncertainties related to new product development and introduction cycles, research and development activities, delays by regulatory authorities, scientific advances by CVD or third parties, introduction of competitive products, third party reimbursement and physician training as well as those factors set forth in the CVD prospectus, dated June 19, 1996. CONTACT: CardioVascular Dynamics, Irvine Heather Murray, 714/457-9546 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion